Proto Labs, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. Proto Labs provides online, quick-turn CNC machining and injection-molding services through its Firstcut and Protomold product lines. Financial statements are unaudited.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Revenue | $46.1 million | $37.3 million; up 23.5% |
| Gross profit / margin | $29.0 million / 63.0% | $23.3 million / 62.4% |
| Operating income / margin | $14.4 million / 31.4% | $11.4 million / 30.5% |
| Net income / diluted EPS | $10.1 million / $0.39 | $8.3 million / $0.32 |
| Operating cash flow | $15.3 million | $11.1 million |
| Cash and cash equivalents | $44.2 million | $43.0 million at Dec. 31, 2013 |
| Marketable securities | $105.7 million | $100.4 million at Dec. 31, 2013 |
| Total debt obligations | $0.3 million | $0.4 million at Dec. 31, 2013 |
At quarter-end, current assets were $110.7 million and current liabilities $16.8 million. Investing cash outflow was $15.7 million, including $9.9 million of property and equipment purchases; financing provided $1.5 million. Cash increased $1.2 million during the quarter. Operating cash flow included significant working-capital movements, including increases in accounts payable and income taxes.
Material changes versus prior year
- Revenue rose across both services: Protomold increased 21.6% to $32.7 million and Firstcut increased 28.2% to $13.4 million. The company served approximately 7,700 product developers, up 18%; average revenue per developer rose 4%.
- International revenue increased 42.4% to $13.1 million, reaching 28.3% of revenue; U.S. revenue increased 17.3%. Foreign-exchange movements added approximately $0.4 million to international revenue.
- Gross margin improved 0.6 percentage points, which management attributed primarily to higher equipment utilization and manufacturing-process efficiencies.
- Operating expenses increased 22.6%, led by higher headcount and investment in marketing, sales and research and development. General and administrative expense also included higher professional-service costs associated with the first Sarbanes-Oxley Section 404 internal-control audit.
- The effective tax rate was 30.6%, versus 27.3%. The prior-year rate benefited from recognition of a $0.3 million research-and-development tax credit.
Outlook, risks and notable items
- No specific revenue or earnings guidance is provided. Management expects operating expenses to rise as it invests in personnel and technology; it expects cost of revenue to increase in dollars but remain relatively constant as a share of revenue, and the effective tax rate to remain relatively constant.
- In April 2014, after quarter-end, Proto Labs acquired FineLine Prototyping, an additive-manufacturing provider, for $34 million cash at closing, with up to $3 million additional cash tied to revenue and integration milestones. The company described the acquisition as not significant to operating results, while identifying integration, unexpected costs or liabilities, customer and employee retention, and potential goodwill impairment as risks.
- The company has foreign-currency exposure and does not hedge it with forward contracts or currency borrowings; management estimated a hypothetical 10% adverse currency move would not materially affect results.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. It did not believe pending ordinary-course legal matters were reasonably expected to have a material adverse effect.
Important facts for investors to verify
- Whether revenue growth, customer growth and average spending per customer continued, especially in international markets.
- Whether gross-margin gains from utilization and process efficiencies persist as capacity and labor costs grow.
- Capital-spending needs and operating cash conversion, including the effect of working-capital fluctuations.
- FineLine’s final purchase-price adjustments, milestone payments, integration progress, and any related goodwill or impairment disclosures.
- Tax-rate comparability, foreign-exchange exposure and the company’s unhedged currency risk.